Aurobindo Pharma’s next big break? CuraTeQ’s biosimilar Zefylti gets UK green light after EU win

CuraTeQ Biologics, a wholly owned step-down subsidiary of Aurobindo Pharma Limited, has received marketing authorisation from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) for its biosimilar product Zefylti. The product is a biosimilar version of filgrastim, a granulocyte colony-stimulating factor used to treat neutropenia in cancer patients undergoing chemotherapy. This marks the second MHRA-approved biosimilar for CuraTeQ, following the approval of Bevqolva in December 2024.

The regulatory greenlight follows Zefylti’s earlier approval in the European Union, where it received marketing authorisation from the European Commission in February 2025. With both UK and EU access secured, CuraTeQ’s entry into the biosimilar market is expected to be a strategic inflection point for Aurobindo Pharma’s biologics ambitions, specifically in oncology and autoimmune therapeutic segments.

What Does the MHRA Approval Mean for CuraTeQ Biologics?

The approval from the MHRA positions CuraTeQ Biologics as a credible biosimilar player in regulated markets. Zefylti is intended to support patients with chemotherapy-induced neutropenia by reducing infection risk and boosting white blood cell counts. In an environment where biologics continue to be cost-prohibitive for many healthcare systems, biosimilars like Zefylti offer a more affordable treatment option.

CuraTeQ’s strategy to target high-volume, high-cost biologics for therapeutic areas such as oncology and immunology has been consistent with global demand for biosimilars. The MHRA nod validates CuraTeQ’s technical, regulatory, and manufacturing capabilities, reaffirming its growing footprint across Europe and the UK.

The product’s approval in the UK also carries post-Brexit relevance. As the UK regulatory landscape operates independently of the European Medicines Agency (EMA), dual clearance from both the EC and MHRA significantly enhances market access and competitive standing.

How Does Zefylti Fit into Aurobindo Pharma’s Biologics Vision?

Aurobindo Pharma has steadily expanded its footprint from generic APIs and formulations into the high-value biologics space. CuraTeQ Biologics is the fulcrum of this pivot, tasked with developing a pipeline of cost-effective, globally competitive biosimilars. With a portfolio of fourteen biosimilars in development, CuraTeQ is focusing primarily on immunology and oncology segments, with end-to-end capabilities from bulk drug substance manufacturing to fill-finish and final packaging.

Zefylti’s addition complements the company’s previously approved biosimilar Bevqolva, a bevacizumab biosimilar used in oncology treatment. The sequence of approvals suggests that CuraTeQ is gaining regulatory momentum and technical validation in some of the most demanding drug approval environments globally.

The company’s Hyderabad-based operations are underpinned by manufacturing facilities that comply with global standards, including approvals from the US Food and Drug Administration (USFDA), European Directorate for the Quality of Medicines (EDQM), and other major health authorities. These facilities not only serve Aurobindo’s generics business but also support biologics scale-up.

What Is the Strategic and Commercial Significance of the Zefylti Launch?

The launch of Zefylti in the UK is expected to enhance CuraTeQ’s revenue diversification and contribute to Aurobindo Pharma’s topline in the near term. Filgrastim biosimilars have already established a sizeable global market, driven by high demand in oncology support therapy. With the UK National Health Service (NHS) under pressure to reduce pharmaceutical expenditure, the approval and eventual commercial roll-out of Zefylti could find ready uptake, especially if price advantages are materialised.

The UK market entry also helps Aurobindo Pharma build brand equity in the branded biosimilar space—traditionally dominated by multinational players with entrenched biologics portfolios. Market analysts suggest that such approvals improve Aurobindo’s pricing power, especially as more competitors enter the biosimilar race, diluting margins in traditional generics.

Furthermore, CuraTeQ’s MHRA-approved products could unlock licensing or co-marketing opportunities with European and UK-based pharmaceutical distributors, facilitating rapid scaling without heavy upfront marketing investments.

How Is Investor Sentiment and Stock Market Performance Reacting?

As of the last trading session prior to the announcement (13 May 2025), Aurobindo Pharma Limited shares (NSE: AUROPHARMA, BSE: 524804) closed modestly higher, with analysts anticipating a medium-term positive re-rating if regulatory momentum continues. Institutional interest in Aurobindo has increased over recent quarters, with Foreign Institutional Investors (FIIs) raising stakes amid a wider portfolio diversification trend toward high-margin biosimilars.

Domestic Institutional Investors (DIIs), including mutual funds and insurance firms, have also shown growing confidence in the biologics roadmap. While short-term gains may be constrained by regulatory timelines and market penetration lag, the strategic narrative around CuraTeQ’s scaling potential is increasingly viewed as a key differentiator within India’s pharma mid-cap segment.

Buy-side analysts have issued ‘Hold’ to ‘Accumulate’ ratings on Aurobindo Pharma post this update, factoring in CuraTeQ’s pipeline visibility and the potential for further approvals in highly regulated markets like the US and Japan. Sell-side sentiment remains cautiously optimistic, with valuation upside contingent on CuraTeQ’s ability to convert regulatory wins into tangible market share.

What’s Next for Aurobindo and CuraTeQ’s Biosimilar Pipeline?

Following the MHRA approval for Zefylti, CuraTeQ’s next focus areas include expanding into additional European jurisdictions and pursuing filings in the U.S. under the FDA’s 351(k) biosimilar pathway. As more originator biologics lose patent protection, particularly in oncology and autoimmune diseases, CuraTeQ’s multi-product pipeline could allow it to establish a recurring revenue stream over the next 3–5 years.

In strategic terms, CuraTeQ’s steady progression also supports Aurobindo Pharma’s aim to become a vertically integrated pharmaceutical leader across generics, APIs, and biologics. The integrated structure enables cost advantages and supply chain agility—a competitive necessity in the biosimilars landscape where price erosion and fast market entry are critical.

Moreover, global health systems continue to encourage biosimilar adoption through policy incentives, volume-based procurement, and faster reimbursement mechanisms. This macro tailwind aligns well with Aurobindo’s cost leadership and CuraTeQ’s growing biosimilar pipeline.

With dual approvals for Zefylti in the EU and UK, CuraTeQ Biologics has not only achieved a significant regulatory milestone but also demonstrated operational credibility in delivering complex biologics. For Aurobindo Pharma, this is a timely reinforcement of its biopharma evolution strategy at a time when investor focus is shifting toward high-value, innovation-led growth segments. Whether CuraTeQ’s momentum can translate into accelerated launches and sustained commercial performance will be closely watched across global pharma and capital markets.